Results 171 to 180 of about 276,101 (206)

Optimizing Treatment, Minimizing Risk: Therapeutic Drug Monitoring in Hematological Malignancies. [PDF]

Mediterr J Hematol Infect Dis
Salmanton-García J, Marchesi F, Cornely OA, Stemler J, Menna P.   +4 more
europepmc   +1 more source

A Biomimetic cRGDyk‐Engineered Platelet Nanoplatform for ACAD11 Delivery to Trigger Pyroptosis in Hepatocellular Carcinoma

Advanced Science, EarlyView.
A biomimetic platelet nanoplatform (OE‐ACAD11@R‐PLT) is developed for targeted hepatocellular carcinoma immunotherapy. By selectively delivering therapeutic plasmids, this system induces mitochondrial dysfunction and triggers robust NLRP3/Caspase‐1/GSDMD‐mediated pyroptosis in tumor cells.
Hongyi Bao, Wei Feng, Wei Zong, Yi Li, Xinyue Qin, Xinyue Wang, Yubo Yang, Guanhua Chen, Yiting Hou, Xuan Tan, Lin Chen, Ming Zhang, Feng Wang   +12 more
wiley   +1 more source

Functional genomics-guided design of CAR-T and CAR-NK therapies in hematological malignancies: aligning cellular engineering with immune escape and microenvironmental resistance. [PDF]

Front Genome Ed
Cai S, Tan Y, Yang Q, Huang J.
europepmc   +1 more source

MicroRNA‐941 Acts as a Novel Prognostic Predictor and Oncogenic Driver in Colorectal Cancer

Annals of Gastroenterological Surgery, EarlyView.
Upregulation of miR‐941 was a promising diagnostic and prognostic biomarker for CRC patients. Inhibition of miR‐941 significantly suppressed CRC cellular events and triggered ferroptosis. The oncogenic functions of miR‐941 were mediated through targeting TRPS1.
Hong Li, Yang Liu, Hua Chen, Jialin Li, Xinchun Li, Yanmin Chen   +5 more
wiley   +1 more source

Prognostic Factors and Clinical Outcomes in Critically Ill Patients with Hematological Malignancies in the Intensive Care Unit. [PDF]

J Clin Med
Yüksel RC, Kaynar AS, Metin H, Temel Ş, Baran Ünal C, Yılmaz Z, Akyol G, Gündoğan K, Sungur M.   +8 more
europepmc   +1 more source

Age‐Dependent Prognostic Significance of Preoperative Transthyretin After Curative Resection for Stage I–III Colorectal Cancer

Annals of Gastroenterological Surgery, EarlyView.
ABSTRACT Background Preoperative malnutrition and systemic inflammation are established determinants of adverse outcomes in colorectal cancer (CRC). Transthyretin (TTR), a rapid‐turnover hepatic protein, reflects both nutritional and inflammatory status; however, its clinical utility may be influenced by age‐ and sex‐related variability.
Ayane Kawata, Yuji Miyamoto, Hiro Nakamura, Takahiko Akiyama, Kota Arima, Katsuhiro Ogawa, Yukiharu Hiyoshi, Masaaki Iwatsuki   +7 more
wiley   +1 more source

Hematological Malignancies With Multiple Primary Cancers: A Rare Case Presentation. [PDF]

Case Rep Hematol
Mahapatra S, Samal P, Samal A, Pandey T, Suse N, Mandava B.   +5 more
europepmc   +1 more source

Navigating Asparaginase Treatment for Patients With Acute Lymphoblastic Leukemia: US Consensus Panel Recommendations on the Role of Multidisciplinary Care

American Journal of Hematology, EarlyView.
ABSTRACT Asparaginase is a critical treatment component for patients with acute lymphoblastic leukemia/lymphoblastic lymphoma (ALL/LBL). However, the successful delivery of asparaginase‐based therapy remains challenging across care settings due to its complex administration, distinct toxicity profile, prolonged treatment duration, and the need for ...
Amir Ali, Grace Elsey, Kayla Fulginiti, Zanette Kanani‐Bradley, Holly R. Kubaney, Sandra Kurtin, Theresa Nguyen, Jennifer Turchina, Charlotte B. Wagner   +8 more
wiley   +1 more source

Nutritional status, dietary antioxidant capacity, and dietary diversity in patients with newly diagnosed hematological malignancies: a case-control study. [PDF]

Support Care Cancer
Koyuncu BN, Yilmaz M, Koseoglu FD.
europepmc   +1 more source

Targeting B‐Cell‐Activating Factor and Its Receptor in Immune Thrombocytopenia and Warm Autoimmune Hemolytic Anemia

American Journal of Hematology, EarlyView.
ABSTRACT Current treatments for immune thrombocytopenia (ITP) and warm autoimmune hemolytic anemia (wAIHA), rare autoimmune diseases in which autoreactive B cells play a major role, can lead to high response rates; however, for many patients these responses are not durable or maintained after treatment discontinuation.
Matthieu Mahévas, Nichola Cooper, Vickie McDonald, Karina Yazdanbakhsh, Wilma Barcellini   +4 more
wiley   +1 more source